Hydrogen Gas Therapy in Schizophrenia: Potential Neuroprotective Effects From an Animal Study
Miyake N, Haga T, Hirano SI, Ichikawa Y, Oguchi Y, Ando K. · Neuropsychopharmacology reports. 2026;46(2):e70117.
What kind of evidence is this?
Preclinical
Controlled preclinical study
Other neurological conditions
Other forms
Not reported in this record.
Not reported in this record.
Methods at a glance
mice, mouse, tissues, tissue used to study other neurological conditions.
Preclinical study; the full text reports 6 mice, with group/assay counts including n=10.
4 weeks
Full text reports H₂-containing gas exposure. Detected intervention quantities or schedules: 4 weeks, 7%, 90 min, 2 L/min.
Molecular H₂ gas exposure at 7%; not classified as Brown’s gas without an H₂/O₂ composition.
H₂-related quantities reported in the intervention passages: 4 weeks, 7%, 90 min, 2 L/min. Values are not combined across different experimental arms.
140 mL/min H₂, calculated from 7% H₂ and 2000 mL/min total flow reported in the full text.
O₂ concentration and absolute O₂ flow were not both reported in the full article; no value is inferred.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
clinical symptoms or functional scores, tumor growth or cancer markers, oxidative-stress and antioxidant markers, neurological or behavioral measures
Article-reported result excerpt (24 words maximum): “MK‐801 significantly reduced whole‐brain HORAC ( p < 0.05), whereas hydrogen gas therapy markedly improved these scores ( p < 0.01).” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. No funding statement was identified in the machine-readable full article; absence is not inferred. No explicit conflict statement was identified in the machine-readable full article; absence is not inferred.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 41944455 · DOI: 10.1002/npr2.70117
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10